Modalis Books Foreign Exchange Gain for FY2025 on Currency Revaluation

Modalis Therapeutics Corporation ( (JP:4883) ) just unveiled an announcement.

Modalis Therapeutics Corporation reported non-operating income of ¥10 million in foreign exchange gains for the fiscal year ended December 31, 2025, driven mainly by the revaluation of its foreign currency-denominated assets and liabilities amid exchange rate fluctuations. The company indicated that the detailed impact of these foreign exchange gains and any related extraordinary losses on its overall earnings is reflected in its consolidated financial results for the same fiscal year, underscoring how currency movements continue to influence its financial performance.

While the reported foreign exchange income is relatively modest in absolute terms, it highlights the company’s financial sensitivity to exchange rate volatility stemming from its international exposure. Stakeholders are directed to the latest consolidated results for a fuller picture of profitability and risk, suggesting that foreign currency effects are an ongoing factor in assessing Modalis Therapeutics’ earnings stability.

The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.

More about Modalis Therapeutics Corporation

Modalis Therapeutics Corporation is a Japan-based biotechnology company listed on the Tokyo Stock Exchange, focusing on therapeutic innovations in the life sciences sector. The company operates in the biopharmaceutical industry, with its performance closely tied to research-driven activities and exposure to foreign currency movements through overseas assets and liabilities.

Average Trading Volume: 837,280

Technical Sentiment Signal: Sell

Current Market Cap: Yen4.99B

For an in-depth examination of 4883 stock, go to TipRanks’ Overview page.